

3 Things You Need to Know About Calciphylaxis: Earlier Intervention, Current Treatments, and Emerging Therapies – Additional Resources

Calciphylaxis: risk factors, diagnosis, and treatment

Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. *Am J Kidney Dis*. 2015;66(1):133-146. doi:10.1053/j.ajkd.2015.01.034

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696752/>

Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis study

Chinnadurai R, Huckle A, Hegarty J, Kalra PA, Sinha S. Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis study. *J Nephrol*. 2021;34(5):1537-1545. doi:10.1007/s40620-020-00908-9

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494680/>

Sodium thiosulfate therapy for calcific uremic arteriolopathy

Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. *Clin J Am Soc Nephrol*. 2013;8(7):1162-1170. doi:10.2215/CJN.09880912

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700696/>

Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD)

Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). *Bonekey Rep*. 2014;3:498. doi:10.1038/bonekey.2013.232

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944129/?report=reader>

The CALCIPHYX study: a randomized, double-blind, placebo-controlled, phase 3 clinical trial of SNF472 for the treatment of calciphylaxis

Sinha S, Gould LJ, Nigwekar SU, et al. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. *Clin Kidney J.* 2021;15(1):136-144. doi:10.1093/ckj/sfab117

Link: <https://academic.oup.com/ckj/article/15/1/136/6316260?login=false>

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

Brandenburg VM, Sinha S, Torregrosa JV, et al. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. *J Nephrol.* 2019;32(5):811-821. doi:10.1007/s40620-019-00631-0

Link: <https://pubmed.ncbi.nlm.nih.gov/31401795/>

KDOQI Clinical Practice Guideline for Hemodialysis Adequacy

National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. *Am J Kidney Dis.* 2015;66(5):884-930. doi:10.1053/j.ajkd.2015.07.015

Link: [https://www.ajkd.org/article/S0272-6386\(15\)01019-7/fulltext](https://www.ajkd.org/article/S0272-6386(15)01019-7/fulltext)